These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21516426)

  • 21. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.
    Fang HB; Ross DD; Sausville E; Tan M
    Stat Med; 2008 Jul; 27(16):3071-83. PubMed ID: 18186545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A flexible unified approach to the analysis of pre-clinical combination studies.
    Harbron C
    Stat Med; 2010 Jul; 29(16):1746-56. PubMed ID: 20572122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.
    El Hassouni B; Mantini G; Li Petri G; Capula M; Boyd L; Weinstein HNW; Vallés-Marti A; Kouwenhoven MCM; Giovannetti E; Westerman BA; Peters GJ;
    Anticancer Res; 2019 Jul; 39(7):3303-3309. PubMed ID: 31262850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
    Chow KU; Boehrer S; Geduldig K; Krapohl A; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2001 May; 86(5):485-93. PubMed ID: 11410411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational approach to the clinical protocol design for drug combinations: a review.
    Chang TT; Chou TC
    Acta Paediatr Taiwan; 2000; 41(6):294-302. PubMed ID: 11198934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neighbor communities in drug combination networks characterize synergistic effect.
    Zou J; Ji P; Zhao YL; Li LL; Wei YQ; Chen YZ; Yang SY
    Mol Biosyst; 2012 Oct; 8(12):3185-96. PubMed ID: 23014807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down?
    Rather MA; Bhat BA; Qurishi MA
    Phytomedicine; 2013 Dec; 21(1):1-14. PubMed ID: 24035674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical versus clinical drug combination studies.
    Chou TC
    Leuk Lymphoma; 2008 Nov; 49(11):2059-80. PubMed ID: 19021049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical analysis of combined dose effects for experiments with two agents.
    Wagenpfeil S; Treiber U; Lehmer A
    Artif Intell Med; 2006 May; 37(1):65-71. PubMed ID: 16497492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer.
    Saputra EC; Huang L; Chen Y; Tucker-Kellogg L
    Cancer Res; 2018 May; 78(9):2419-2431. PubMed ID: 29686021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic principles for combination therapy.
    Toews ML; Bylund DB
    Proc Am Thorac Soc; 2005; 2(4):282-9; discussion 290-1. PubMed ID: 16267349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method.
    Zhang N; Fu JN; Chou TC
    Am J Cancer Res; 2016; 6(1):97-104. PubMed ID: 27073727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental design and statistical analysis for three-drug combination studies.
    Fang HB; Chen X; Pei XY; Grant S; Tan M
    Stat Methods Med Res; 2017 Jun; 26(3):1261-1280. PubMed ID: 25744107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening drug target combinations in disease-related molecular networks.
    Luo M; Jiao J; Wang R
    BMC Bioinformatics; 2019 May; 20(Suppl 7):198. PubMed ID: 31074386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methods for detecting chemical-chemical interaction in toxicology.
    Bhat AS; Ahangar AA
    Toxicol Mech Methods; 2007; 17(8):441-50. PubMed ID: 20020870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of dose-response curve analysis in delineating shared or different molecular sites of action for osteolathyrogens.
    Dawson DA; Scott BD; Ellenberger MJ; Pöch G; Rinaldi AC
    Environ Toxicol Pharmacol; 2004 Mar; 16(1-2):13-23. PubMed ID: 21782690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.